PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR TREATMENT OF RETINAL DISEASES
申请人:Fuso Pharmaceutical Industries, Ltd.
公开号:EP3919052A1
公开(公告)日:2021-12-08
The present invention provides a pharmaceutical composition for intraocular administration or oral administration, for preventing or treating a retinal disease (such as age-related macular degeneration), or suppressing a progression of the disease in a subject in need of treatment, the composition comprising an effective amount of one or more compounds selected from the following group, and a pharmaceutically acceptable carrier; and a method threfor, a group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine and indapamide.
本发明提供了一种用于眼内给药或口服给药的药物组合物,用于预防或治疗视网膜疾病(如老年性黄斑变性),或抑制需要治疗的受试者的疾病进展,该组合物包括有效量的选自下组的一种或多种化合物,以及药学上可接受的载体;以及一种方法,其中包括阿朴吗啡、艾舍洛林、乙氧基喹、甲基多巴、奥氮平和吲达帕胺。